% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • encore7 encore7 Jun 14, 2013 10:01 AM Flag

    Why no analyst recommendation to the shorts??

    Don't they deserve some sage advice too? The following would be appropriate now IMHO:

    Encore Investment Analytics Inc makes cautious comments on Sarepta short position. With 40% of stock now short, short sellers risk major losses on any further positive indications regarding FDA AA request. Expected inclusion of SRPT in Russell 2000 index provides further major risk to short view. Recommend reducing short position ahead of any positive catalysts.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
18.738+0.818(+4.56%)10:55 AMEDT